Geographic Atrophy Treatment

Jun 07, 2024

Wet AMD, comprising around 10% of the total AMD population, is primarily the target of pharmaceutical companies, representing a market worth billions of dollars. With only two FDA-approved treatments, dry AMD presents a substantial market potential, encompassing approximately 90% of all AMD patients. Key players...

Aug 18, 2023

Globally, more than 5 million people are affected by geographic atrophy. Also, as per the published study by the GER group, the global prevalence of geographic atrophy is 0.66% in all ages, but it occurs in 0.34% for 65–74 years old, 1.3% for 75–84, and 4.4% over 85 years old. Geographic atrophy is a progressive, i...